Bayer says Nexavar misses target in liver cancer trial
FRANKFURT, March 11
FRANKFURT, March 11 (Reuters) - Germany's Bayer said a Phase III trial of cancer drug Nexavar as an adjuvant therapy for liver cancer did not meet its main target.
"We are disappointed that the trial did not meet its primary endpoint," said Joerg Moeller, member of the Bayer HealthCare Executive Committee. "However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer."
Nexavar, or sorafenib, is made by Bayer and Onyx Pharmaceuticals, and is already approved to treat advanced kidney cancer and liver cancer that cannot be surgically removed.
- Seven NATO allies to create new rapid reaction force-report
- U.S. authorities investigate suspected threat against Obama: reports
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- Putin says Russia must strengthen its economic, military position in Arctic
- Lights off on Singapore's billionaire row as luxury house prices plunge